Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance

Cancer Research

Volumn 75, Issue 5, 2015, Pages 880-891

  Javidi Sharifi, Nathalie ^a,b   Traer, Elie ^a,b   Martinez, Jacqueline ^a   Gupta, Anu ^c   Taguchi, Takehiro ^d   Dunlap, Jennifer ^a   Heinrich, Michael C ^a,b,e   Corless, Christopher L ^a   Rubin, Brian P ^c,f   Druker, Brian J ^a,b,g   Tyner, Jeffrey W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d KOCHI UNIVERSITY   (Japan)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; POLO LIKE KINASE 1; SMALL INTERFERING RNA; BENZAMIDE DERIVATIVE; FGFR3 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE SILENCING; GROWTH INHIBITION; IC50; IMMUNOPRECIPITATION; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GASTROINTESTINAL STROMAL TUMORS; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BENZAMIDES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GASTROINTESTINAL STROMAL TUMORS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; IMATINIB MESYLATE; IMMUNOPRECIPITATION; MAP KINASE SIGNALING SYSTEM; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR CROSS-TALK; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA, SMALL INTERFERING;

EID: 84928803593     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0573     Document Type: Article

References (35)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78.
2. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001;193:505-10.
3. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7.
4. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
5. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007;26:7560-8.
6. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010;467:849-53.
7. Schlemmer M, Bauer S, Schütte R, Hartmann J, Bokemeyer C, Hosius C, et al. Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial. Eur J Med Res 2011;16:206-12.
8. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32.
9. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008;216:64-74.
10. Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 2011;17:283-92.
11. Di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012;2012:429213.
12. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-8.
13. Onwuazor ON, Wen X-Y, Wang D-Y, Zhuang L, Masih-Khan E, Claudio J, et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003;102:772-3.
14. Li Z. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001;97:2413-9.
15. Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 2012;130:2857-66.
16. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-24.
17. Yang F, Strand DW, Rowley DR. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene 2008;27:450-9.
18. Murphy T, Darby S, Mathers ME, Gnanapragasam VJ. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010;220:452-60.
19. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008;111:2238-45.
20. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 2009;106:8695-700.
21. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t (1;19) acute lymphoblastic leukemia. Cancer Cell 2012;22:656-67.
22. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49.
23. Johnson MD, O'Connell MJ, Pilcher W, Reeder JE. Fibroblast growth factor receptor-3 expression inmeningiomaswith stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg 2010;112:934-9.
24. Tomlinson D, Knowles M, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 2012;130:2857-66.
25. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong X-Q, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 2012;287:28087-98.
26. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011;437:199-213.
27. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 2010;5:e14117.
28. Semrad TJ, Mack PC. Fibroblast growth factor signaling in non-small-cell lung cancer. Clin Lung Cancer 2012;13:90-5.
29. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2013;2:e39.
30. Salm F, Cwiek P, Ghosal A, Lucia Buccarello A, Largey F, Wotzkow C, et al. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. Oncogene 2013;32:3944-53.
31. Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 2006;25:3078-88.
32. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non - small-cell lung cancer cells. Cell Prolif 2009;75:196-207.
33. Huynh H, Lee J W J, Chow P K H, Ngo VC, Lew GB, Lam I W L, et al. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther 2009;8:152-9.
34. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. TargetingMET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009;10:709-17.
35. Yokote H, Fujita K, Jing X, Sawada T, Liang S, Yao L, et al. Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc Natl Acad Sci U S A 2005;102:18866-71.